Skip to content

Treatment of uncomplicated chronic constipation with Unani medicine

An open-label randomized controlled clinical study to compare the efficacy and safety of Saboos Isapgol with Syrup Cremaffin in patients with uncomplicated Da’imi-Qabz (Chronic Constipation) - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/068120
Enrollment
60
Registered
2024-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

Intervention1: Saboos Isapgol: Dose-12gm, Frequency-Single dose at bed time. Route of administration- Orally. Duration- 4 weeks. Control Intervention1: Syrup Cremaffin: Dose-15ml Frequency-Single dose

Sponsors

Government Tibbi College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having the complaints of: 1.Abdominal pain or discomfort 2.Reduced bowel movements (less than 3/week) or infrequent stools 3.Sense of incomplete evacuation 4.Nausea or flatulence 5.Pain at defecation 6.Straining at defecation 7.Patient willing to sign the written informed consent to participate in this trial.

Exclusion criteria

Exclusion criteria: 1.Below 20 years and above 60 years of patient. 2.Pregnant and lactating women. 3.Patients taking other drugs such as atropine and opium group. 4.Patients taking any antacid medicine which has aluminium and calcium. 5.Associated Complications like Diabetes mellitus, Hypertension, Hyperthyroidism, anal fistula, anal fissure, haemorrhoids, hernia, ano-rectal abscess, etc. 6.Mentally retarded person and prisoners. 7.Patients with chronic debilitating diseases, or neurologic abnormalities. 8.Non ambulatory / Bed ridden patients. 9.One who had previous surgery of the colon. 10.Patient having diagnosed intestinal structural abnormality. 11.Patient with phlegmatic temperament. 12.Patient who’s not agree to give consent

Design outcomes

Primary

MeasureTime frame
Stool frequency (Number of stools per week) Stool consistency (1- hard; 2- firm; 3- loose)Timepoint: baseline, 1st Follow up at the end of second week

Secondary

MeasureTime frame
Assessment according to ROME Diagnostic CriteriaTimepoint: 2nd Follow up at the end of fourth weeks

Countries

India

Contacts

Public ContactDr Md Najibur Rahman

Government Tibbi College and Hospital

amudrshahnawaz@gmail.com9411209323

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026